Jump to content
Powered by
  • BIOPRO BW
  • Healthcare industry
  • Bioeconomy

Healthcare industry

Main navigation

  • Start page
  • Healthcare industry BW

    Healthcare industry BW

    Close
    • At a glance
    • The biotechnology sector
    • Medical technology
    • The pharmaceutical industry
    • Training & university education
    • Company foundation
    • Infrastructure
    • Clusters & Networks
  • Articles

    Articles

    Close
    • Latest news
    • Selected press releases
    • Dossiers
    • Red biotechnology
    • Medical technology
    • Pharmaceutics
    • Diagnostics
    • Basic research
    • Selected publications
  • Events

    Events

    Close
  • Databases

    Databases

    Close
    • Funding
    • Healthcare industry database
    • Research institutions
  • BIOPRO services

    BIOPRO services

    Close
    • BIOPRO services and offers
    • Contacts
    • Information channels
  • de
  • en
Show menu

You are here:

  1. Home
  2. Search
Show:Results per page
  • 25Show results
  • 50Show results
  • 75Show results

Search Results

  • Article - 14/01/2021 Sven-Diederichs_Teaser.jpg

    Newly discovered RNA as growth driver in liver cancer

    Non-coding RNA (ncRNAs) molecules that do not encode proteins have many different functions, and some are associated with certain diseases. Prof. Dr. Sven Diederichs from the German Consortium for Translational Cancer Research and the German Cancer Research Center in Heidelberg has been conducting research into these molecules at the Freiburg University Medical Centre and discovered a ncRNA that regulates cell proliferation in cancer cells.

    https:////www.gesundheitsindustrie-bw.de/en/article/news/newly-discovered-rna-growth-driver-liver-cancer
  • Press release - 09/12/2020

    Combatting cancer with biological circuits

    The Freiburg engineer and biologist Prof. Dr. Barbara Di Ventura receives a Consolidator Grant from the European Research Council (ERC), one of the most prestigious prizes for European researchers, for her project "InCanTeSiMo - Intelligent cancer therapy with synthetic biology methods". Di Ventura will use the 2 Million Euros to develop a novel cancer treatment based on molecular methods from synthetic biology.

    https:////www.gesundheitsindustrie-bw.de/en/article/press-release/combatting-cancer-biological-circuits
  • Press release - 04/11/2020

    Which treatment is best for childhood brain tumors? Global trial receives funding of EUR 2.2m

    The German Childhood Cancer Foundation is providing EUR 2.2m to fund the phase III clinical trial to investigate the treatment options for certain types of childhood brain cancer with a chronic course. Initiated by the Hopp Children’s Cancer Center Heidelberg, the trial will compare two standard chemotherapy treatments and a targeted therapy to establish which is the most effective and well tolerated as a standard therapy for young patients.

    https:////www.gesundheitsindustrie-bw.de/en/article/press-release/welche-behandlung-ist-die-beste-bei-hirntumoren-im-kindesalter-weltweite-studie-wird-mit-22-mio-euro-gefoerdert
  • Atriva Therapeutics - 21/10/2020 Kulturschalen mit blau angefärbten Zellen, zu denen das neue Coronavirus (SARS CoV-2) gegeben wurde. Die mit dem Wirkstoff ATR-002 von Atriva Therapeutics behandelten Zellen (rechte Reihen) zeigen keine weißen Löcher im Zellrasen und somit keine Zellzerstörung.

    COVID-19 pioneer drug in Phase II clinical trial – with double the power

    The effective treatment of people with severe COVID-19 is a major goal during the corona pandemic. ATR-002, an oral small molecule that targets RNA viruses such as influenza virus and SARS-CoV-2, has a dual effect: it impairs viral propagation and also has an immunomodulatory effect. And what’s more, due to its unique cellular mechanism of action, the efficacy of Atrivia Therapeutics’ drug candidate is not reduced by virus mutations and…

    https:////www.gesundheitsindustrie-bw.de/en/article/news/covid-19-pioneer-drug-phase-ii-clinical-trial-double-power
  • Press release - 15/10/2020

    Pancreatic cancer: Subtypes with different aggressiveness discovered

    Tumors of the pancreas are particularly feared. They are usually discovered late and mortality is high. Until now, no targeted and personalized therapies exist. Scientists at the German Cancer Research Center (DKFZ) and the Heidelberg Institute for Stem Cell Technology and Experimental Medicine* (HI-STEM) have now succeeded for the first time in defining two differently aggressive molecular subtypes of pancreatic carcinoma.

    https:////www.gesundheitsindustrie-bw.de/en/article/press-release/pancreatic-cancer-subtypes-different-aggressiveness-discovered
  • Organ failure due to fatty liver - 24/09/2020 AdobeStock_9729015_SciePro_Leber_Mensch.jpg

    HepaRegeniX develops an active substance for liver regeneration

    When the liver stops regenerating on its own, it might be possible in future for doctors to intervene with a chemical agent. Tübingen-based HepaRegeniX GmbH is developing a promising candidate with the aim of improving the treatment of both acute and chronic liver failure.

    https:////www.gesundheitsindustrie-bw.de/en/article/news/heparegenix-develops-active-substance-liver-regeneration
  • Microstructure Technology - 17/07/2020 eNase_Bild_4.jpg

    An electronic nose for many applications

    Sensory organs are sophisticated masterpieces of nature. That is why humans have often tried to copy them. Be it cameras or microphones - there are technical objects that have always been based on natural models such as the eye or the ear. For a long time, however, no artificial sense of smell has featured in the technical repertoire. Now researchers at the Karlsruhe Institute of Technology (KIT) have developed an electronic nose. It can…

    https:////www.gesundheitsindustrie-bw.de/en/article/news/electronic-nose-many-applications
  • Press release - 27/09/2018

    One hundred percent success

    Two Clusters of Excellence for the University of Freiburg: Biological Signalling Studies and Bioinspired Materials Research. It is a major boost to cutting-edge research in Freiburg: in the current Excellence Strategy competition, scientists at the University of Freiburg have been granted two Clusters of Excellence, CIBSS – Centre for Integrative Biological Signalling Studies, and livMatS – Living, Adaptive and Energy-autonomous Materials…

    https:////www.gesundheitsindustrie-bw.de/en/article/press-release/one-hundred-percent-success
  • Article - 21/02/2018 The diagram highlights the importance of the MKK4 kinase enzyme in people with liver injury. Activation of MKK4 can lead to hepatic failure and death, or severe fibrosis. This is shown on the left-hand side of the diagram. Inhibition of MKK4 accelerates the replication of hepatocytes and prevents their apoptosis, thereby permitting successful regeneration of the liver. In the worst case, inhibition of MKK4 leads to light fibrosis only. The result of MKK inhibition is shown on the right-hand side of the diagram.

    HepaRegeniX – a start-up is taking it up a step!

    HepaRegeniX, a biotech company founded in 2016, specialises in developing drugs that restore the regenerative capacity of diseased livers. The three founders of the biotech start-up, Prof. Dr. Lars Zender, Prof. Dr. Stefan Laufer and Dr. Wolfgang Albrecht, anticipate starting clinical testing of the first drug candidate in 2019.

    https:////www.gesundheitsindustrie-bw.de/en/article/news/heparegenix-a-start-up-is-taking-it-up-a-step
  • Press release - 21/09/2017

    Atriva reaches a development milestone and receives an additional tranche of running seed financing to develop its influenza therapeutic to clinical stage

    The next generation of Antiviral Therapies: Co-Led by Stichting Participatie Atriva and High-Tech Gründerfonds (HTGF), Atriva Therapeutics GmbH has received a second tranche of its running seed financing in total of € 3 Mn from Dutch, German and Canadian investors, after lead compound ATR-002 (Atriva’s antiviral MEK-Inhibitor against Influenza) has passed an important preclinical milestone paving the way to clinical development stage.

    https:////www.gesundheitsindustrie-bw.de/en/article/press-release/atriva-reaches-a-development-milestone-and-receives-an-additional-tranche-of-running-seed-financing-to-develop-its-influenza-the
  • Article - 04/07/2017 The photo shows Prof. Dr. Nikolas von Bubnoff and Prof. Dr. Robert Zeiser at the award ceremony.

    Ruxolitinib – successful graft-versus-host disease treatment

    Graft-versus-host disease is a serious complication in leukaemia patients who have been given a blood stem cell transplant from a genetically different person. Prof. Dr. Nikolas von Bubnoff and Prof. Dr. Robert Zeiser from the Department of Haematology, Oncology and Stem Cell Transplantation at Freiburg University Medical Centre initiated a Germany-wide study to show that an active substance called ruxolitinib has a promising therapeutic effect.…

    https:////www.gesundheitsindustrie-bw.de/en/article/news/ruxolitinib-successful-graft-versus-host-disease-treatment
  • Press release - 07/02/2017

    Atriva receives seed financing to develop its next generation influenza therapeutic

    The next generation of Antiviral Therapies: Led by Stichting Participatie Atriva together with High-Tech Gründerfonds (HTGF), Atriva Therapeutics GmbH has received seed financing from Dutch and German private investors to advance Atriva’s antiviral MEK-Inhibitors (Mitogen-activated protein kinase kinase inhibitor) against Influenza into the clinical development stage.

    https:////www.gesundheitsindustrie-bw.de/en/article/press-release/atriva-receives-seed-financing-to-develop-its-next-generation-influenza-therapeutic
  • Article - 12/09/2016 Photo of the building housing the Department of Internal Medicine in Tübingen.

    New target for the therapy of hepatocellular carcinoma discovered

    Hepatocellular carcinoma is the second most common cause of cancer deaths worldwide. If the tumour is at an advanced stage, doctors have few treatment options. Researchers led by Prof. Dr. Lars Zender from the University of Tübingen have now identified one of the cancer's Achilles' heels, namely, the interaction between C-MYC and AURKA proteins, which can be destabilised with a drug, thus killing cancer cells.

    https:////www.gesundheitsindustrie-bw.de/en/article/news/new-target-for-the-therapy-of-hepatocellular-carcinoma-discovered
  • Article - 05/09/2016 Glioblastom_MRT.jpg

    Apogenix: immuno-oncological protein drugs for the treatment of malignant diseases

    Apogenix AG, a biopharmaceutical company from Heidelberg that specialises in immuno-oncology, develops protein drugs that target central signalling pathways involved in regulating the growth, migration and apoptosis of malfunctioning cells and thus offer novel treatment options for cancer and other malignant diseases.

    https:////www.gesundheitsindustrie-bw.de/en/article/news/apogenix-immunonkologische-proteinwirkstoffe-gegen-maligne-erkrankungen
  • Article - 02/06/2016 B/W photo showing the logo "KIT" against a black background.

    DNA origami for decoding the language of biological cells

    Cells have their own language that they use to communicate with each other. They need this language to be able to form intact tissues and fulfil their specific functions in the body. If these signalling pathways are disrupted, metabolic processes will suffer and result in diseases. We know many “words” of the cellular language, i.e. signalling molecules that bind to specific surface receptors and thereby trigger chemical reactions inside the…

    https:////www.gesundheitsindustrie-bw.de/en/article/news/dna-origami-for-decoding-the-language-of-biological-cells
  • Article - 13/01/2016 Drawing from the book "Max and Moritz" showing teacher Lämpel about to go to bed. A prohibition sign is    drawn across the bed.

    New approach for treating depression

    Depression is the most common mental health condition; it must be taken seriously and requires treatment. Exactly how and where therapies work is still unclear. Prof. Dr. Dietrich van Calker and Prof. Dr. Knut Biber from Freiburg University Medical Center have been looking into mechanisms of action and have discovered a molecule that appears to be implicated in numerous neuropsychiatric disorders and the effect of various anti-depression…

    https:////www.gesundheitsindustrie-bw.de/en/article/news/new-approach-for-treating-depression
  • Article - 07/01/2016 Schematic showing a B-cell receptor in the plasma membrane and the protein Kidins220.

    New protein helps B cells generate an effective immune response

    The human immune system plays a key role for human health. Dr. Gina Fiala, a scientist in Prof. Dr. Wolfgang Schamel’s team in the Department of Immunology at Freiburg University, has discovered Kidins220/ARMS in B cells. Kidins220/ARMS is part of the adaptive immune system where it plays a key role in the maturation of B cells.

    https:////www.gesundheitsindustrie-bw.de/en/article/news/kidins220-hilft-b-zellen-bei-der-immunabwehr
  • Researcher profile - 09/11/2015 Boutros_Michael_2015_2.jpg

    Michael Boutros – from the study of social gene networks to the management of the DKFZ

    Deregulation of cell signalling pathways is a major driver of cancer. Prof. Dr. Michael Boutros has pioneered the development of new methods for the analysis of genetic interactions in such complex networks. He has been acting Chairman and Scientific Member of the Management Board of the German Cancer Research Center (DKFZ) since September 1st 2015.

    https:////www.gesundheitsindustrie-bw.de/en/article/news/michael-boutros-from-the-study-of-social-gene-networks-to-the-management-of-the-dkfz
  • Article - 03/09/2015 Coloured photo of Patrick Müller touching a shelf with a fish tank with zebrafish.

    Pattern formation: How undifferentiated cell clusters develop orderly structures

    Dr. Patrick Müller explores cellular signalling pathways that turn undifferentiated cell clusters into orderly structures as embryos develop. Supported by an ERC grant, the Max Planck researcher from Tübingen uses a broad range of methods from the fields of genetics, biophysics, mathematics and the computer sciences for his investigations. Regenerative medicine is one field that particularly stands to benefit from Müller’s findings.

    https:////www.gesundheitsindustrie-bw.de/en/article/news/pattern-formation-how-undifferentiated-cell-clusters-develop-orderly-structures
  • Article - 26/05/2015 The photo shows two scientists looking into the camera.

    Novel effect of B-Raf inhibitors against bowel cancer discovered

    Colorectal carcinoma is the most frequent type of bowel cancer and the second most common tumour disease in men and women in Germany. A particularly aggressive form occurs when a mutation is present in the proto-oncogene BRAF. As part of the Collaborative Research Centre 850 at the Institute of Molecular Medicine and Cell Research at the University of Freiburg, Dr. Ricarda Herr and Dr. Tilman Brummer are trying to find out how a mutated BRAF gene…

    https:////www.gesundheitsindustrie-bw.de/en/article/news/novel-effect-of-b-raf-inhibitors-against-bowel-cancer-discovered
  • Article - 23/02/2015 Photo of a young woman smiling into the camera.

    Miriam Erlacher: apoptosis research – balancing clinical work and research

    Programmed cell death plays an important role in embryonic development and has also been identified as the cause of a range of diseases. It also plays a key role in the development and survival of higher organisms. Its regulation is based on a sophisticated system of interacting antagonistic signals in a network that is still largely unknown. Disturbances in this delicate balance promote the development of diseases such as cancer. Dr. Miriam…

    https:////www.gesundheitsindustrie-bw.de/en/article/news/miriam-erlacher-apoptosis-research-balancing-clinical-work-and-research
  • Article - 23/02/2015 Hans Kestler, bioinformatician from Ulm, pointing at a scientific poster.

    Systems biology: Ulm scientists' search for molecules that delay ageing

    As stem cells get older, they gradually lose their ability to grow and reproduce. They accumulate damage and lose their ability to regenerate, thus knocking tissue homeostasis off balance. If stem cell ageing could be delayed or, even better, reversed, organs would work longer more effectively. The SyStaR research consortium is using systems biology methods and tools to investigate the mechanisms of age-dependent reduction of stem cell function…

    https:////www.gesundheitsindustrie-bw.de/en/article/news/systems-biology-ulm-scientists-search-for-molecules-that-delay-ageing
  • Article - 08/09/2014 Dr. Maria Moreno-Villanueva, University of Konstanz

    Molecular effects of traumatic stress

    After a traumatic experience, people often suffer not only mental, but also physical effects. Dr. María Moreno-Villanueva from the University of Konstanz has investigated the molecular effects of traumatic stress in people and has found a higher than normal number of DNA strand breaks. In the worst cases this can lead to diseases such as cancer. However, her study also shows that successful psychotherapy can reverse DNA damage. Her findings will…

    https:////www.gesundheitsindustrie-bw.de/en/article/news/molecular-effects-of-traumatic-stress
  • Press release - 15/07/2014 21805_de.jpg

    amcure Receives EUR 5 Million Funding for the Development of New Tumour Therapeutic Agents

    amcure GmbH, a spin-off from the Karlsruhe Institute of Technology (KIT), has closed a Series A financing deal amounting to a total of EUR 5 million. The funding comes from a consortium headed by LBBW Venture Capital, with participations from KfW, MBG Mittelständische Beteiligungsgesellschaft Baden-Wuerttemberg, S-Kap Beteiligungen Pforzheim, BioM AG as well as private investors. The company also receives subsidies from the German Ministry of…

    https:////www.gesundheitsindustrie-bw.de/en/article/press-release/amcure-receives-eur-5-million-funding-for-the-development-of-new-tumour-therapeutic-agents
  • Article - 10/06/2014 Photo of junior professor Nicole Radde

    Mathematical models for predicting cellular signalling pathways

    The micrometre-sized cells in organisms are biological systems in which countless vital processes take place. However little is yet known about most of these cellular metabolic chains because they interact with each other in a complicated manner. The research carried out by junior professor Nicole Radde and her doctoral student and engineer Patrick Weber from the Institute for Systems Theory and Automated Control IST at the University of…

    https:////www.gesundheitsindustrie-bw.de/en/article/news/mathematical-models-for-predicting-cellular-signalling-pathways

Page 1 / 6

sb_search.block.search_result.other.pages

  • 1
  • 2
  • 3
  • 4
  • 5
  • 6
  • eine Seite zurück
  • Extend search to all portals
  • Search the Healthcare industry database
  • Search the Research institutions
Search terms
Portal
Information type
  • Type
    Event date
    From
    To
  • Type
  • Publication date
    Topics
    Topics
  • Publication date
Reset

Footer navigation

  • Healthcare industry BW
    • At a glance
    • The biotechnology sector
    • Medical technology
    • The pharmaceutical industry
    • Training & university education
    • Company foundation
    • Infrastructure
    • Clusters & Networks
  • Articles
    • Latest news
    • Selected press releases
    • Dossiers
    • Red biotechnology
    • Medical technology
    • Pharmaceutics
    • Diagnostics
    • Basic research
    • Selected publications
  • Events
  • Databases
    • Funding
    • Healthcare industry database
    • Research institutions
  • BIOPRO services
    • BIOPRO services and offers
    • Contacts
    • Information channels
  • Project pages
    • Telemedicine BW
    • MDR & IVDR
  • Portals
    • BIOPRO BW
    • Healthcare industry
    • Bioeconomy
  • To top

stay informed

Subscribe to newsletter

Social Media

  • Xing
  • Twitter
  • LinkedIn
  • Rss
  • Privacy statement
  • Legal notice
  • Sitemap
  • Contact
© 2021
Website address: https://www.gesundheitsindustrie-bw.de/en/search